# Clinical Trial Landscape: 08_lung_squamous_pd_l1_high

*Generated: 2026-01-05 06:58:20*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 7

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 29 | █████ 29.0% |
| Phase 1 | 23 | ████ 23.0% |
| Phase 1/Phase 2 | 20 | ████ 20.0% |
| Phase 3 | 10 | ██ 10.0% |
| Unknown | 8 | █ 8.0% |
| Not Applicable | 6 | █ 6.0% |
| Phase 2/Phase 3 | 3 |  3.0% |
| Early Phase 1 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 97 (97.0%)
- **Not yet recruiting**: 2 (2.0%)
- **Enrolling by invitation**: 1 (1.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| Merck Sharp & Dohme LLC | 6 |
| M.D. Anderson Cancer Center | 4 |
| AbbVie | 4 |
| AstraZeneca | 4 |
| Amgen | 3 |
| National Cancer Institute (NCI) | 2 |
| University of Colorado, Denver | 2 |
| Wake Forest University Health Sciences | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| SWOG Cancer Research Network | 2 |
| Eli Lilly and Company | 2 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Precision Biologics, Inc | 1 |
| Dana-Farber Cancer Institute | 1 |
| Baylor College of Medicine | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Carboplatin | 15 |
| Pembrolizumab | 14 |
| Pemetrexed | 13 |
| Cisplatin | 9 |
| Nivolumab | 8 |
| Osimertinib | 6 |
| Paclitaxel | 6 |
| Docetaxel | 5 |
| Questionnaire Administration | 4 |
| Biospecimen Collection | 4 |
| Durvalumab | 4 |
| Computed Tomography | 3 |
| Magnetic Resonance Imaging | 3 |
| Gemcitabine | 3 |
| Nab-paclitaxel | 3 |
| Bevacizumab | 3 |
| pembrolizumab | 3 |
| carboplatin | 3 |
| JAB-23E73 | 3 |
| laboratory biomarker analysis | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 31 |
| South Korea | 25 |
| France | 24 |
| Japan | 23 |
| Italy | 20 |
| China | 19 |
| Australia | 18 |
| United Kingdom | 17 |
| Taiwan | 17 |
| Canada | 16 |
| Poland | 16 |
| Germany | 16 |
| Israel | 15 |
| Belgium | 15 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| squamous cell lung cancer | manual | 1.0 |
| PD-L1 TPS ≥90% squamous cell lung cancer | llm | 0.9 |
| PD-L1 TPS ≥90% metastatic squamous cell lung cancer | llm | 0.9 |
| PD-L1 TPS ≥90% NSCLC | llm | 0.9 |
| metastatic squamous cell lung cancer | llm | 0.8 |
| NSCLC | llm | 0.8 |
| PD-L1 TPS ≥90% | llm | 0.9 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06996782](https://clinicaltrials.gov/study/NCT06996782) | Phase 1/Phase 2 | Recruiting | AstraZeneca | A Phase Ib/II Open-Label, Multicent... |
| [NCT06671613](https://clinicaltrials.gov/study/NCT06671613) | Not Applicable | Recruiting | VA Office of Researc... | Evaluating the Impact of Intermitte... |
| [NCT07132918](https://clinicaltrials.gov/study/NCT07132918) | Phase 2 | Recruiting | University of Wiscon... | The cARdiac Radiation Therapy Spari... |
| [NCT04119024](https://clinicaltrials.gov/study/NCT04119024) | Phase 1 | Recruiting | Anusha Kalbasi | Phase I Dose Escalation Study of Sy... |
| [NCT06712745](https://clinicaltrials.gov/study/NCT06712745) | Early Phase 1 | Recruiting | University of Texas ... | Feasibility Study of Personalized U... |
| [NCT06814496](https://clinicaltrials.gov/study/NCT06814496) | Phase 1/Phase 2 | Recruiting | University of Arizon... | RAdiation comBined With BIspecific ... |
| [NCT07005102](https://clinicaltrials.gov/study/NCT07005102) | Phase 2/Phase 3 | Recruiting | AbbVie | A Phase 2/3 Randomized Study to Eva... |
| [NCT07073183](https://clinicaltrials.gov/study/NCT07073183) | Phase 1 | Not yet recruiting | CureVac | A Phase I Dose-Finding Study to Eva... |
| [NCT06933329](https://clinicaltrials.gov/study/NCT06933329) | Phase 2 | Recruiting | BicycleTx Limited | Phase 2 Study of Zelenectide Pevedo... |
| [NCT06973564](https://clinicaltrials.gov/study/NCT06973564) | Phase 1/Phase 2 | Recruiting | Jacobio Pharmaceutic... | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06780098](https://clinicaltrials.gov/study/NCT06780098) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | KEYMAKER-U01 Substudy 01I: A Phase ... |
| [NCT06780085](https://clinicaltrials.gov/study/NCT06780085) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | KEYMAKER-U01 Substudy 01H: A Phase ... |
| [NCT06975293](https://clinicaltrials.gov/study/NCT06975293) | Phase 1/Phase 2 | Recruiting | STORM Therapeutics L... | Open-label, Non-randomized, Multi-c... |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Phase 3 | Recruiting | Mirati Therapeutics ... | A Randomized, Double-Blind, Phase 3... |
| [NCT06385262](https://clinicaltrials.gov/study/NCT06385262) | Phase 2 | Recruiting | Duke University | Safety, Efficacy, and Tumor Immune ... |
| [NCT06568939](https://clinicaltrials.gov/study/NCT06568939) | Phase 2 | Recruiting | AbbVie | A Phase 2, Open-Label, Randomized, ... |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Phase 2 | Recruiting | Jazz Pharmaceuticals | A Phase 2, Open-label, Multicenter ... |
| [NCT05669846](https://clinicaltrials.gov/study/NCT05669846) | Phase 2 | Recruiting | Diwakar Davar | Phase II Feasibility Study of Healt... |
| [NCT06593522](https://clinicaltrials.gov/study/NCT06593522) | Phase 2 | Recruiting | Amgen | A Phase 2 Study Evaluating the Effi... |
| [NCT06657222](https://clinicaltrials.gov/study/NCT06657222) | Phase 1/Phase 2 | Recruiting | Tubulis GmbH | A Multicenter FIH Dose Escalation a... |
| [NCT06472245](https://clinicaltrials.gov/study/NCT06472245) | Phase 3 | Recruiting | OSE Immunotherapeuti... | A Randomised, Open-label, Phase 3 T... |
| [NCT06627647](https://clinicaltrials.gov/study/NCT06627647) | Phase 3 | Recruiting | AstraZeneca | A Phase III, Randomized, Double-bli... |
| [NCT06116682](https://clinicaltrials.gov/study/NCT06116682) | Phase 2 | Recruiting | SWOG Cancer Research... | A Phase II Study of Amivantamab SC ... |
| [NCT06566443](https://clinicaltrials.gov/study/NCT06566443) | Phase 1 | Recruiting | The Methodist Hospit... | Phase I Trial Evaluating the Safety... |
| [NCT06561386](https://clinicaltrials.gov/study/NCT06561386) | Phase 3 | Recruiting | Bristol-Myers Squibb | A Phase 3, Randomized, Open-label S... |
| [NCT06463665](https://clinicaltrials.gov/study/NCT06463665) | Phase 2 | Recruiting | Genelux Corporation | A Randomized Phase 2 Study Assessin... |
| [NCT06311721](https://clinicaltrials.gov/study/NCT06311721) | Phase 3 | Recruiting | Amgen | A Randomized, Double-Blind Study to... |
| [NCT06545331](https://clinicaltrials.gov/study/NCT06545331) | Phase 1 | Recruiting | Exelixis | A Dose-Escalation and Expansion Stu... |
| [NCT06252129](https://clinicaltrials.gov/study/NCT06252129) | Not Applicable | Recruiting | Brigham and Women's ... | Maximizing Lymph Node Dissection on... |
| [NCT06427941](https://clinicaltrials.gov/study/NCT06427941) | Phase 1 | Recruiting | BeOne Medicines | A Phase 1 Study Investigating the S... |
| [NCT06465069](https://clinicaltrials.gov/study/NCT06465069) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Study of LY4052031, a... |
| [NCT06548672](https://clinicaltrials.gov/study/NCT06548672) | Phase 1 | Recruiting | Biocity Biopharmaceu... | A Phase Ia/Ib, Open-Label, Dose Esc... |
| [NCT06305754](https://clinicaltrials.gov/study/NCT06305754) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Randomized, Open-label, Phase 3 S... |
| [NCT06422143](https://clinicaltrials.gov/study/NCT06422143) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | Phase 3 Study of Pembrolizumab in C... |
| [NCT06400472](https://clinicaltrials.gov/study/NCT06400472) | Phase 1 | Recruiting | Eli Lilly and Compan... | A First-in-Human, Phase 1a/1b Trial... |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Phase 2 | Recruiting | Mayo Clinic | Pilot Single-Arm, Pragmatic Trial o... |
| [NCT06236438](https://clinicaltrials.gov/study/NCT06236438) | Phase 2/Phase 3 | Recruiting | AbbVie | A Randomized, Phase 2/3 Study to Ev... |
| [NCT06124118](https://clinicaltrials.gov/study/NCT06124118) | Phase 1 | Recruiting | University of Utah | A Feasibility Study to Evaluate the... |
| [NCT06312137](https://clinicaltrials.gov/study/NCT06312137) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3 Randomized Open-Label Stu... |
| [NCT06253871](https://clinicaltrials.gov/study/NCT06253871) | Phase 1 | Recruiting | Iambic Therapeutics,... | A Phase 1/1b Study of IAM1363 in Pa... |
| [NCT06225804](https://clinicaltrials.gov/study/NCT06225804) | Phase 1 | Recruiting | Abbisko Therapeutics... | A Phase 1, Open-Label Study of ABSK... |
| [NCT06033196](https://clinicaltrials.gov/study/NCT06033196) | Phase 2 | Recruiting | National Institute o... | Targeting Inflammation and Alloimmu... |
| [NCT06151574](https://clinicaltrials.gov/study/NCT06151574) | Phase 3 | Recruiting | Boehringer Ingelheim | Beamion LUNG 2: A Phase III, Open-l... |
| [NCT06403436](https://clinicaltrials.gov/study/NCT06403436) | Phase 1 | Recruiting | TOLREMO therapeutics... | A Phase 1, First-in-Human, Open-lab... |
| [NCT06090266](https://clinicaltrials.gov/study/NCT06090266) | Phase 1/Phase 2 | Recruiting | OncoResponse, Inc. | A Phase 1/2 Study of OR502 Alone an... |
| [NCT05715229](https://clinicaltrials.gov/study/NCT05715229) | Phase 2 | Recruiting | Hackensack Meridian ... | A Multicenter Phase II Randomized T... |
| [NCT06050707](https://clinicaltrials.gov/study/NCT06050707) | Phase 2 | Recruiting | University Health Ne... | MR-Adaptive Radiation Therapy for A... |
| [NCT05815173](https://clinicaltrials.gov/study/NCT05815173) | Phase 1 | Recruiting | NYU Langone Health | Phase I/II Study of Ladarixin and S... |
| [NCT05845671](https://clinicaltrials.gov/study/NCT05845671) | Phase 1/Phase 2 | Recruiting | University of Colora... | A Phase 1 / 2, Open Label, Study of... |
| [NCT05520099](https://clinicaltrials.gov/study/NCT05520099) | N/A | Recruiting | Elephas | Observational Basket Trial to Colle... |

*... and 50 more trials (see trials.csv for full list)*
